🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06859190
Recruiting Phase 3

Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer

NCT06859190 · tracked via the Priya Life Science China tracker
Sponsor
Qinghai Red Cross Hospital
Phase
Phase 3
Started
2025-03-01
Last updated
2025-03-25

Condition(s) studied

CancerInsomnia

Investigational drug(s) / intervention(s)

estazolam 1-2 mgAuricular pressure bean combined with electroacupuncture

estazolam 1-2 mg: oral estazolam 1-2 mg daily at bedtime for 8 weeks.

Auricular pressure bean combined with electroacupuncture: Electroacupuncture treatment will be performed on seven acupoints, including Baihui (GV20), Shenting (GV24), Yintang (GV29), Anmian (EX-HN22), Shenmen (HT7), Neiguan (PC6), and Sanyinjiao (SP6). Each session lasts for 30 minutes and is conducted twice a week.In addition, auricular point seed-pressing therapy will be applied to bilateral auricular points related to insomnia (Shenmen, Heart, and Sympathetic). Each auricular point will be pressed for 1 minute, three times a day. The total treatment course is eight weeks.

Study summary

The core objectives of this study are to assess the short-term and long-term efficacy of auricular acupoint pressure beans combined with electroacupuncture and estazolam in the treatment of cancer-caused insomnia. The study aims to accurately compare the differences between this combination therapy and standard Western medicine in improving sleep quality and effectively alleviating anxiety and depression. Additionally, it will meticulously observe the safety of the combined treatment and record the occurrence and potential causative factors of any adverse reactions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. Age 18 and above. 2. The diagnosis of a malignant solid tumor was confirmed by pathological examination. 3. Clinically diagnosed cancer-caused insomnia with insomnia symptoms lasting more than 1 month, more than 3 or more times per week. 4. An Insomnia Severity Index (ISI) score of 8 or higher and meets the criteria for insomnia disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition. 5. No medications related to the treatment of insomnia have been used in the last 1 month. 6. No serious dysfunction of the heart, liver, kidneys or other vital organs. 7. Patients volunteered to participate in this study and signed an informed consent form. Exclusion Criteria: 1. Irregular sleep-wake cycles in jobs with shift demands or due to inconsistent work schedules. 2. Inadequately treated for another sleep disorder (e.g., sleep disorder disorders such as sleep apnea obstruction syndrome, restless leg syndrome, etc.). 3. Received acupuncture or auricular pressure bean therapy within the past 3 months. 4. Estimated life expectancy is ≥3 months. 5. Have a history of severe allergies, especially to the drugs or treatments used in this study. 6. History of severe mental illness with a current episode. 7. History of substance abuse or alcohol dependence.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
China, Qinghai,Qinghai Red Cross Hospital Xining Qinghai Recruiting

More Qinghai Red Cross Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06859190 on ClinicalTrials.gov ↗ ← All trials in China